Alyftrek in Sri Lanka
How patients in Sri Lanka access Alyftrek (pegvaliase) via Named Patient Program.
Alyftrek - overview
Alyftrek (pegvaliase) is manufactured by BioMarin Pharmaceutical and indicated for Phenylketonuria. It is a Small molecule approved by the US FDA in 2024 and may be accessible to patients in Sri Lanka through a Named Patient Program or personal-import pathway.
Access in Sri Lanka
Sri Lanka's NMRA permits named-patient import for rare-disease specialty drugs via physician request.
How Reserve Meds coordinates access in Sri Lanka
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Sri Lanka-specific eligibility.
- Treating physician in Sri Lanka issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Alyftrek from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Sri Lanka.
Typical timeline for Sri Lanka
End-to-end, most requests are completed in 2-6 weeks. Sri Lanka's tier 3 regulatory maturity typically supports longer processing times.
What patients and physicians in Sri Lanka ask
- Is the pathway legal in Sri Lanka? Yes - it operates under Sri Lanka's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Sri Lanka able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.
Start a request for Alyftrek in Sri Lanka
GREEN
AI Regulatory Review Agent — preliminary signal
Small-molecule specialty therapy with clear personal import pathway in Sri Lanka via NMRA. Oral delivery; standard logistics.
Rule: sm_specialty_clear_pathway • Reviewed 2026-04-22